These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 25621159)

  • 41. Transitioning From Intravenous to Subcutaneous Prostacyclin Therapy in Neonates With Severe Pulmonary Hypertension.
    Turbenson MN; Radosevich JJ; Manuel V; Feldman J
    J Pediatr Pharmacol Ther; 2020; 25(7):647-653. PubMed ID: 33041721
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Implementing the EXPEDITE parenteral induction protocol: Rapid parenteral treprostinil titration and transition to oral treprostinil.
    Kingrey JF; Miller CE; Franco V; Smith JS; Zolty R; Oudiz RJ; Elwing JM; Huston JH; Melendres-Groves L; Ravichandran A; Balasubramanian V; Wu B; Hwang S; Seaman S; Broderick M; Rahaghi FF
    Pulm Circ; 2023 Jul; 13(3):e12255. PubMed ID: 37497167
    [TBL] [Abstract][Full Text] [Related]  

  • 43. BREEZE: Open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension.
    Spikes LA; Bajwa AA; Burger CD; Desai SV; Eggert MS; El-Kersh KA; Fisher MR; Johri S; Joly JM; Mehta J; Palevsky HI; Ramani GV; Restrepo-Jaramillo R; Sahay S; Shah TG; Deng C; Miceli M; Smith P; Shapiro SM
    Pulm Circ; 2022 Apr; 12(2):e12063. PubMed ID: 35514770
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Transition of Intravenous Treprostinil to Oral Therapy in a Patient with Functional Class IV Chronic Thromboembolic Pulmonary Hypertension.
    Thurber KM; Williams BM; Bates RE; Frantz RP
    Pharmacotherapy; 2017 Aug; 37(8):e76-e81. PubMed ID: 28513869
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension.
    Vachiéry JL; Hill N; Zwicke D; Barst R; Blackburn S; Naeije R
    Chest; 2002 May; 121(5):1561-5. PubMed ID: 12006444
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safe and successful transition from oral selexipag to subcutaneous treprostinil in a patient with idiopathic pulmonary arterial hypertension treated with triple combination therapy.
    Adachi S; Nishiyama I; Yasuda K; Yoshida M; Nakano Y; Kondo T; Murohara T
    J Cardiol Cases; 2022 Jul; 26(1):42-45. PubMed ID: 35923524
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension.
    Gomberg-Maitland M; Tapson VF; Benza RL; McLaughlin VV; Krichman A; Widlitz AC; Barst RJ
    Am J Respir Crit Care Med; 2005 Dec; 172(12):1586-9. PubMed ID: 16151039
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical utility of treprostinil in the treatment of pulmonary arterial hypertension: an evidence-based review.
    Buckley MS; Berry AJ; Kazem NH; Patel SA; Librodo PA
    Core Evid; 2014; 9():71-80. PubMed ID: 25018685
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Direct prostacyclin transition in pediatric patients with pulmonary hypertension.
    Merrill K; Davis A; Jackson E; Riker M; Kirk C; Yung D
    Pulm Circ; 2024 Apr; 14(2):e12373. PubMed ID: 38706991
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease.
    Oudiz RJ; Schilz RJ; Barst RJ; Galié N; Rich S; Rubin LJ; Simonneau G;
    Chest; 2004 Aug; 126(2):420-7. PubMed ID: 15302727
    [TBL] [Abstract][Full Text] [Related]  

  • 51. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
    Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
    J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Resource utilization at the time of prostacyclin initiation in children in pulmonary arterial hypertension: a multicenter analysis.
    Hart SA; Arora G; Feingold B
    Pulm Circ; 2018; 8(1):2045893217753357. PubMed ID: 29313743
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension.
    Sitbon O; Manes A; Jais X; Pallazini M; Humbert M; Presotto L; Paillette Ld; Zaccardelli D; Davis G; Jeffs R; Simonneau G; Galie N
    J Cardiovasc Pharmacol; 2007 Jan; 49(1):1-5. PubMed ID: 17261956
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension.
    Suleman N; Frost AE
    Chest; 2004 Sep; 126(3):808-15. PubMed ID: 15364760
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and Tolerability of High-dose Inhaled Treprostinil in Pulmonary Hypertension.
    Parikh KS; Rajagopal S; Fortin T; Tapson VF; Poms AD
    J Cardiovasc Pharmacol; 2016 Apr; 67(4):322-5. PubMed ID: 26828324
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of subcutaneous treprostinil in pediatric pulmonary arterial hypertension-Bridge-to-transplant or long-term treatment?
    Ablonczy L; Tordas D; Kis E; Szatmári A
    Pediatr Transplant; 2018 Mar; 22(2):. PubMed ID: 29266571
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension.
    Ferrantino M; White RJ
    Expert Opin Pharmacother; 2011 Nov; 12(16):2583-93. PubMed ID: 21988216
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A systematic review of transition studies of pulmonary arterial hypertension specific medications.
    Sofer A; Ryan MJ; Tedford RJ; Wirth JA; Fares WH
    Pulm Circ; 2017; 7(2):326-338. PubMed ID: 28597769
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial.
    Rubenfire M; McLaughlin VV; Allen RP; Elliott G; Park MH; Wade M; Schilz R
    Chest; 2007 Sep; 132(3):757-63. PubMed ID: 17400684
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial.
    White RJ; Jerjes-Sanchez C; Bohns Meyer GM; Pulido T; Sepulveda P; Wang KY; Grünig E; Hiremath S; Yu Z; Gangcheng Z; Yip WLJ; Zhang S; Khan A; Deng CQ; Grover R; Tapson VF;
    Am J Respir Crit Care Med; 2020 Mar; 201(6):707-717. PubMed ID: 31765604
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.